Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

15.54
+0.21501.40%
Volume:713.66K
Turnover:11.08M
Market Cap:3.13B
PE:-18.80
High:15.66
Open:15.40
Low:15.40
Close:15.32
52wk High:16.20
52wk Low:9.84
Shares:201.40M
Float Shares:195.63M
Volume Ratio:0.33
T/O Rate:0.36%
Dividend:1
Dividend Rate:6.44%
EPS(TTM):-0.8265
EPS(LYR):-1.4300
ROE:-4.86%
ROA:2.75%
PB:1.01
PE(LYR):-10.86

Loading ...

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

GlobeNewswire
·
Jul 28

Press Release: Samsung Epis Holdings Reports Second Quarter and Half-year 2026 Financial Results

Dow Jones
·
Jul 24

How Investors Are Reacting To Park Hotels & Resorts (PK) New Value Rating Amid Cost Pressures

Simply Wall St.
·
Jul 23

Park Hotels Reopens Royal Palm South Beach Miami After USD 100 Million Renovation

Reuters
·
Jul 23

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

GlobeNewswire
·
Jul 21

Is Park Hotels & Resorts (PK) Undervalued Following Positive Analyst Sentiment?

Simply Wall St.
·
Jul 21

Park Hotels & Resorts is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 18

Lawyer Denies Febrie Adriansyah Received Money from Tan Kian

Tempo
·
Jul 18

Morgan Stanley Adjusts PT on Park Hotels & Resorts to $11 From $10.50, Maintains Equalweight Rating

MT Newswires Live
·
Jul 17

Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins

GlobeNewswire
·
Jul 16

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

GlobeNewswire
·
Jul 12

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

GlobeNewswire
·
Jul 12

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

GlobeNewswire
·
Jul 08

U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

GlobeNewswire
·
Jul 07

Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

GlobeNewswire
·
Jun 29

PRF Technologies Reports Expanded Preclinical Results for PRF-110 in Head-to-Head Comparison with Approved Benchmark

GlobeNewswire
·
Jun 25

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

GlobeNewswire
·
Jun 24

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

GlobeNewswire
·
Jun 22

Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Jun 18

Park Hotels & Resorts, Inc. : Wells Fargo Raises Target Price to $15 From $12

THOMSON REUTERS
·
Jun 18